Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.275 USD | +1.19% | -6.57% | +3.23% |
04-23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
04-16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.23% | 264M | |
-2.96% | 102B | |
+2.01% | 96.09B | |
+2.13% | 22.28B | |
-17.12% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-14.01% | 16.09B | |
+5.99% | 13.83B | |
+32.74% | 11.97B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Akebia Therapeutics : Cantor Fitzgerald Initiates Coverage on Akebia Therapeutics With Overweight Rating, $8 Price Target